Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3K8VM)

Drug Name

BMS-908662 Drug Info

Synonyms

BMS-908662; XL281; BMS 908662; BMS-908662 free base; 870603-16-0; GTPL7968; SCHEMBL10049428; SCHEMBL20299316; CHEMBL3545027; EXEL-2819; Carbamic acid, (5-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydro; BMS908662; XL-281; XL 281; DB12854; Carbamic acid, N-(6-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)carbamate, (+/-)-; Methyl (5-(2-(5-chloro-2-methyl

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 56931136
CAS Number: CAS 870603-16-0
TTD Drug ID: DM3K8VM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase B-raf (BRAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[3]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[4]
LGX818	DMNQXV8	Melanoma	2C30	Approved	[5]
PLX8394	DMRTD7I	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
BGB-283	DMVYTG7	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
ARQ 736	DMP9ZT1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RO-5212054	DML4C3Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
ASN003	DMJCX6D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
ABM-1310	DMS1HR3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7968).
2	Clinical pipeline report, company report or official report of Exelixis (2011).
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
7	Clinical pipeline report, company report or official report of Ambit Biosciences.
8	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
9	National Cancer Institute Drug Dictionary (drug id 688029).
10	National Cancer Institute Drug Dictionary (drug id 680347).
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Clinical pipeline report, company report or official report of ABM Therapeutics.